Schaeffer's Top Stock Picks for '25

Dismal Sales Warning Has Retail Stock Spiraling to New Lows

Hibbett will unveil its full quarterly earnings report on Aug. 18

Managing Editor
Jul 24, 2017 at 10:09 AM
facebook X logo linkedin


U.S. stocks are trading mixed ahead of a busy week of earnings. Among specific equities in the news are oil services giant Halliburton Company (NYSE:HAL), retailer Hibbett Sports, Inc. (NASDAQ:HIBB), and biotech stock Genocea Biosciences Inc (NASDAQ:GNCA). Here's a quick look at what's moving shares of HAL, HIBB, and GNCA.

Earnings Beat Can't Save Halliburton Stock 

Halliburton stock was up 2% at the open, after the company reported adjusted profit of 23 cents per share on $4.96 billion in sales -- exceeding analysts' expectations. Nevertheless, the shares have since swung 2.7% lower to trade at $43.19. It's been a tough year for HAL stock, which is down 20% year-to-date, with last week's rally attempt quickly halted by its 80-day moving average.

Nevertheless, analysts have remained confident in HAL stock. Of  the 22 brokerages covering HAL shares, 18 rate it a "strong buy." Continued technical struggles could have analysts re-evaluating their upbeat outlooks.

Same-Store Sales Warning Has HIBB Stock Reeling

Hibbett Sports shares are down 26.6% to trade at $14.45 -- earlier hitting an eight-year low of $14.20 -- after the company said it expects second-quarter same-store sales to fall by roughly 10%, and will likely record a per-share loss of 19 cents to 22 cents for the period. HIBB stock is now staring at a stiff 61% year-to-date deficit.

Although the security is short-sale restricted today, short sellers have been betting on more downside recently. Short interest jumped 30% in the two most recent reporting periods, and now accounts for 22.5% of HIBB's available float. Hibbett Sports is scheduled to report earnings the morning of Friday, Aug. 18.

Positive Drug Data Has Genocea Stock Climbing

Genocea Biosciences stock is up 9.1% to trade at $5.51, after the company reported its GEN-003 drug for genital herpes achieved positive results for its mid-stage trials. GNCA stock has been reeling since topping out at an annual high of $7.29 on April 25, and is now trading north of its 40-day moving average -- a trendline that served as a stiff ceiling for the shares in mid-May and early June.

These recent technical struggles have likely been exacerbated by a sharp rise in short interest. These bearish bets increased by 41% during the last reporting period, and now account for nearly one-fifth of the stock's total available float.

 
 

Which of These SUB-$5 Stocks Could 26x From Here? (AD)

He called a rare 11x on Tesla…

Then he called a 26x on Workhorse…

Then an even rarer 35x on Nio Inc…

Now Tim Bohen says these 5 tiny “America First” stocks are next up in 2025.

They’re trading for less than $5 right now.

But thanks to Elon & Trump’s new alliance…

They could be off to the races in Trump’s first 100 days.

And right now for a limited time…

You can get the names & tickers for just $1 here. (AD)

10 Stock Picks FREE
 
 

Featured Articles from Trusted Partners:

🚀 One Stock Pick Could Change Everything in 2025
What if one stock pick could define your success next year? Get 10 expert-vetted stocks set for 2025—plus 5 bonus picks to watch now. Get the Report →

🆕 New Options Need New Trading Strategies
Zero-DTE options are the newest (and hottest) options to trade.  Professional traders have rushed into the market and are making a mint.  Don’t get left behind - learn all about these options, how to trade them, market setups to profit from, plus much more. Download now →

👀 Revealed: 3 Defensive Stocks for Your Portfolio
Worried about the market? This free report reveals 3 under-the-radar defensive stocks for uncertain times in any kind of economy.

 

 
 

FREE Report Download

 

Follow us on X, Follow us on Twitter